Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TYRA
TYRA BIOSCIENCES, INC.
NASDAQ
$28.65
▲ UP 15.25% (3.79)

KEY STATISTICS

Market Cap$1.71 B
52w High$40.65
52w Low$11.70
Dividend Yield—
Frequency—
P/E-11.94
Volume1.86M
Shares Out.59.66M

COMPANY

LEADERSHIP

Todd Harris
CHIEF EXECUTIVE
Todd Harris

COMPENSATION 2026

Salary$658,000
Stock Awards$0
Incentive Plan Pay$325,710
All Other Comp.$15,250
Total$5,566,997

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 15, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
87

PRICE TARGET

Target High$54.00
Target Low$42.00
Target Median$48.00
Target Consensus$48.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$28.65 ▲ UP 15.25% (+$3.79)
$25.50$27.00$28.509:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM28.65

About Tyra Biosciences, Inc.

https://www.tyra.bio ↗

Tyra Biosciences, Inc., a preclinical-stage biotech in Carlsbad, develops targeted cancer therapies, including TYRA-300 for bladder cancer, and utilizes its SNAP platform for rapid molecular design.

INDUSTRY

Biotechnology

A PRODUCT TYRA BIOSCIENCES, INC. IS KNOWN FOR

Dabogratinib (formerly TYRA-300)
Dabogratinib (formerly TYRA-300)

Dabogratinib, Tyra Biosciences' lead oral FGFR3 inhibitor, is in Phase 2 trials for cancers like bladder cancer and skeletal dysplasias such as achondroplasia, representing their primary clinical development focus.

COMPETITORS

COMPETITOR
ASND COMPARE
BBIO COMPARE
BMRN COMPARE
INCY COMPARE
RLAY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
128
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.32% · 1.5M
VTS.AX
0.00% · 1.1M
XSU.TO
0.03% · 937.5K
SCHA
0.02% · 140.3K
USVM
0.15% · 108.9K
SBIO
0.82% · 80.3K
TMSL
0.07% · 78.2K
FESM
0.03% · 75.5K
CANC
0.83% · 72.9K
DFMC
0.02% · 62.2K
LABU
0.21% · 49.5K
XRS2.DE
0.03% · 33.4K
GSSC
0.04% · 19.2K
RSSL
0.03% · 17.6K
BBC
0.57% · 11.6K
BBSC
0.01% · 3.8K
IBBQ
0.10% · 3.7K
RTWP.L
0.04% · 3.1K
ESSC
0.17% · 2.5K
BIB
0.05% · 2.1K
VIRS
0.07% · 646
USUE.DE
0.00% · 124
RESM
0.04% · 86
AVSU
0.00% · 10

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
207
TOP 12 OF 207 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
12.2M sh · $389.62M
Fmr LLC
8.9M sh · $284.92M
Boxer Capital, LLC
6.4M sh · $151.6M
Alta Partners Management Company, L.P.
4.1M sh · $57.08M
Nextech Invest, Ltd.
4.1M sh · $56.74M
Nextech Invest Ltd.
4.1M sh · $56.38M
Janus Henderson Group Plc
3.9M sh · $148.87M
Bvf Inc/Il
3.6M sh · $51.06M
Canaan Partners Xi LLC
3.6M sh · $50.48M
Farallon Capital Management LLC
3.6M sh · $137.15M
Commodore Capital LP
3.4M sh · $88.73M
Tcg Crossover Management, LLC
3.2M sh · $103.77M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
MORE ROBERT J
Purchase · 13.2K shares
2026-05-28
★
DIRECTOR
Rothenberg Stephen Michael
Purchase · 13.2K shares
2026-05-28
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 13.2K shares
2026-05-28
★
DIRECTOR
Verjee Rehan
Purchase · 13.2K shares
2026-05-28

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 2
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY B of A Securities BUY Piper Sandler OVERWEIGHT Wedbush OUTPERFORM Jefferies BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
NBTX$38.65COMPARE
KURA$13.15COMPARE
SVRA$5.35COMPARE
MRVI$7.42COMPARE
GERN$1.53COMPARE
PRME$3.72COMPARE
RZLT$4.62COMPARE
EYPT$4.63COMPARE